Clinical Research Directory

Inclusion Criteria: * Patients must be ≥ 18 years of age and must sign the ICF and be capable of giving written informed consent * Patients must have either experienced disease recurrence or progression following standard systemic therapy, been intolerant of or ineligible for standard therapy, have no standard treatment available or no satisfactory alternative treatment as determined by the investigator. * Tumors harboring actionable genomic alterations, patients must have experienced disease recurrence or progression following ≥ 1 approved targeted therapy for advanced or metastatic disease, where applicable. * For Phase 1b, patients with advanced or metastatic disease in select solid tumors must have received ≥ 1 but no more than 2 or 3 prior lines of systemic therapy for advanced or metastatic disease. * Patients must provide agreement for collection of tumor tissue samples. * Must have ≥ 1 measurable lesion as assessed by RECIST v1.1. * Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Adequate organ function * Must be willing to use effective birth control for the duration of the study Exclusion Criteria: * History of severe allergic reactions or hypersensitivity to other monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), or trispecific antibodies (TsAbs), or the active ingredients and excipients of BON-106. * Active leptomeningeal disease, primary brain tumors, or uncontrolled, untreated brain metastasis. * Active autoimmune diseases that may relapse. * Patients with immunodeficiency as assessed by the investigator to be not suitable for treatment with immune modulating anticancer agents, prior allogeneic stem cell transplantation, or organ transplantation. * Patients with infection (including tuberculosis infection, or other) requiring systemic antibacterial, antifungal, or antiviral therapy ≤ 14 days before the first dose of study drug(s). NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.